LSD1 is up-regulated in multiple YAPoff cancers [58–60], and LSD1 inhibitors show strong, although sometimes variable, efficacy against these cancers [58–64] and are currently being tested in clinical trials for SCLC and other NE cancers [65]. Here, KDM1A is linked to cancer.